Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Liabilities and Shareholders Equity (2016 - 2025)

Regenxbio (RGNX) has 12 years of Liabilities and Shareholders Equity data on record, last reported at $453.0 million in Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 2.78% year-over-year to $453.0 million; the TTM value through Dec 2025 reached $2.1 billion, down 6.11%, while the annual FY2025 figure was $453.0 million, 2.78% down from the prior year.
  • Liabilities and Shareholders Equity reached $453.0 million in Q4 2025 per RGNX's latest filing, down from $525.2 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.1 billion in Q4 2021 and bottomed at $453.0 million in Q4 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $709.9 million, with a median of $658.1 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 89.56% in 2021, then crashed 31.12% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.1 billion in 2021, then decreased by 25.19% to $833.3 million in 2022, then plummeted by 31.12% to $574.0 million in 2023, then decreased by 18.81% to $466.0 million in 2024, then dropped by 2.78% to $453.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $453.0 million in Q4 2025, $525.2 million in Q3 2025, and $581.0 million in Q2 2025.